Background & Aims: Hepatitis B is a potentially life-threatening liver infection and it
is a major global health problem. Over the past decade, numerous studies have reported that patients
with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D
levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in
chronic hepatitis B patients, before and during treatment with antiviral therapy.
Methods: It was a prospective study in which 80 subjects were enrolled between December 2017
and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were
recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once
daily. Full routine laboratory investigations, HBV DNA measurement by real-time PCR were
conducted once before initiation of antiviral treatment and again at least 6 months later. Serum vitamin
D level [25(OH)D3 was assessed twice, once before initiation of antiviral treatment and
again at least 6 months later. This was done for all the patients enrolled in the study.
Results: The studied cases showed a significantly low mean serum Vitamin D level when assessed
before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3
ng/ml) which was comparable to that of the control group (33.4 ± 5 ng/ml).
Conclusion: The present study highlights the impact of antiviral therapy on vitamin D deficiency
in CHB patients, where effective therapy improves vitamin D levels. Meanwhile, it is recommended
to study the impact of vitamin D replacement and correction on the disease progression or